Subramanyam Maddala has joined AMRI as president of its India Operations. He takes responsibility for AMRI’s Indian API manufacturing operations as well as AMRI facility operations in Hyderabad and Aurangabad.
Maddala brings more than 20 years of operations, business development, and senior leadership experience in the manufacturing of APIs and intermediates, custom synthesis, and formulations in branded and generics markets to the Albany, US-headquartered firm. Most recently, he was vice president, Contract Research and Manufacturing Services (CRAMS) and New Generics for Shasun Pharmaceuticals, and was responsible for Shasun’s contract research and manufacturing business, including all vertical CRAMs businesses and new API generic efforts. Prior to that, he held several roles of increasing responsibility at Piramal India, Glenmark Pharmaceuticals, Medicorp/Matrix Labs, Torrent Pharmaceuticals, SOL and Lupin Laboratories.
Dr Rajesh Shenoy
Dr Rajesh Shenoy, managing director, AMRI India, is relocating back to the US, where he will take the position of director, project management-pharmaceutical services. Shenoy will have full leadership responsibilities for AMRI’s global project management activities throughout the pharmaceutical services sector, including small scale, large scale, GMP activities, formulations development and manufacturing, and sterile fill and finish.
Shenoy joined AMRI in 1998 and prior to his six-year assignment in India, held positions of increasing responsibility in AMRI’s discovery and development services operations.
